Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Follow The Leader: Looking Across The IO Landscape, An Infographic

Executive Summary

While interest in immuno-oncology runs deep across the industry, a handful of companies are leading the pack. Scrip offers a side-by-side look at the IO portfolios for BMS, Merck, Roche and AstraZeneca.

You may also be interested in...



2017 – Scrip Readers’ Pharma Year In Review

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

2017 – Scrip Readers’ Pharma Year In Review

As we enter a new year, Scrip reviews some of the biggest overall themes which attracted our readers over the last 12 months.

Pipeline Watch: Six New Approvals And 20 Phase III Updates

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC099063

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel